p53 Mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis

Blood

Volumn 87, Issue 10, 1996, Pages 4302-4310

  Greiner, Timothy C ^a   Moynihan, Michael J ^a   Chan, Wing C ^a   Lytle, Debra M ^a   Pedersen, Alex ^a   Anderson, James R ^a   Weisenburger, Dennis D ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER CYTODIAGNOSIS; CANCER SURVIVAL; DIAGNOSTIC VALUE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOMA; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MISSENSE MUTATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 0029916234     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.10.4302.bloodjournal87104302     Document Type: Article

References (85)

1. Weisenburger DD: Mantle cell lymphoma, in Knowles DM (ed): Neoplastic Hematopathology. Baltimore, MD, Williams & Wilkins, 1992, p 617
2. Raffeld M, Jaffe ES: bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood 78:259, 1991
3. Zucca E, Stein H, Coiffier B: European Lymphoma Task Force (ELTF): Report of the workshop on mantle cell lymphoma (MCL). Ann Oncol 5:507, 1994
4. Berard CW, Dorfman RF: Histopathology of malignant lymphomas. Clin Haematol 3:39, 1974
5. Lennert K, Stein H, Kaiserling E: Cytological and functional criteria for the classification of malignant lymphomata. Br J Cancer 31:29, 1975 (suppl II)
6. Weisenburger DD, Nathwani BN, Diamond LW, Winberg CD, Rappaport H: Malignant lymphoma, intermediate lymphocytic type: A clinicopathologic study of 42 cases. Cancer 48:1415, 1981
7. Weisenburger DD, Kim H, Rappaport H: Mantle-zone lymphoma: A follicular variant of intermediate lymphocytic lymphoma. Cancer 49:1429, 1982
8. Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphoma: Summary and description of a working formulation for clinical usage. Cancer 49:2112, 1982
9. Jaffe ES, Bookman MA, Longo DL: Lymphocytic lymphoma of intermediate differentiation-mantle zone lymphoma: A distinct subtype of B-cell lymphoma. Hum Pathol 18:877, 1987
10. Lardelli P, Bookman MA, Sundeen J, Longo DL, Jaffe ES: Lymphocytic lymphoma of intermediate differentiation: Morphologic and immunophenotypic spectrum and clinical correlations. Am J Surg Pathol 14:752, 1990
11. Mederios LJ, Jaffe ES: Low-grade B-cell lymphomas not specified in the working formulation, in Jaffe ES (ed): Surgical Pathology of the Lymph Nodes and Related Organs. Philadelphia, PA, Saunders, 1995, p 221
12. Lennert K, Mohri N: Histopathology and diagnosis of non-Hodgkin's lymphomas: Malignant lymphoma, centrocytic (Centrocytoma), in Lennert K (ed): Malignant Lymphomas Other Than Hodgkin's Disease. Berlin, Germany, Springer-Verlag, 1978, p 284
13. Ott MM, Ott G, Kuse R, Porowski P, Gunzer U, Feller AC, Müller-Hermelink HK: The anaplastic variant of centrocytic lymphoma is marked by frequent rearrangements of the bcl-1 gene and high proliferation indices. Histopathology 24:329, 1994
14. Weisenburger DD, Sanger WG, Armitage JO, Purtilo DT: Intermediate lymphocytic lymphoma: Immunophenotypic and cytogenetic findings. Blood 69:1617, 1987
15. Leroux D, LeMerc'hadour F, Gressin R, Jacob M-C, Keddari E, Monteil M, Caillot P, Jalbert P, Sotto JJ: Non-Hodgkin's lymphoma with t(11;14)(q13;q32): A subset of mantle zone/intermediate lymphocytic lymphoma? Br J Haematol 77:346, 1991
16. Vandenberghe E, De Wolf-Peeters C, van den Oord J, Wlodarski I, Delabie J, Stul M, Thomas J, Michaux JL, Mecucci C, Cassiman JJ, van den Berghe H: Translocation (11; 14): A cytogenetic anomaly associated with B-cell lymphomas of non-follicle centre cell lineage. J Pathol 163:13, 1991
17. Mederios LJ, Van Krieken JH, Jaffe ES, Raffeld M: Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation. Blood 76:2086, 1990
18. Rimokh R, Berger F, Delsol G, Charrin C, Berthéas M-F, Ffrench M, Garoscio M, Felman P, Coiffier B, Bryon P-A, Rochet M, Gentilhomme O, Germain D, Magaud J-P: Rearrangement and overexpression of the BCL-1/PRAD-1 gene in intermediate lymphocytic lymphomas and in t(11q13)-bearing leukemias. Blood 81:3063, 1993
19. Williams ME, Swerdlow SH, Rosenberg CL, Arnold A: Characterization of chromosome 11 translocation breakpoints at the bcl-1 and PRAD1 loci in centrocytic lymphoma. Cancer Res 52:5541s, 1992 (suppl)
20. de Boer CJ, Loyson S, Kluin PM, Kluin-Nelemans HC, Schuuring E, van Krieken JHJM: Multiple breakpoints within the bcl-1 locus in B-cell lympoma: Rearrangements of the cyclin D1 gene. Cancer Res 53:4148, 1993
21. Rimokh R, Berger F, Delsol G, Charrin C, Berthéas, Ffrench M, Garoscio M, Felman P, Coiffier B, Bryon, P-A, Rochet M, Gentilhomme O, Germain D, Magaud J-P: Rearrangement and overexpression of the BCL-1/PRAD-1 gene in intermediate lymphocytic lymphomas and in t(11q13)-bearing leukemias. Blood 81:3063, 1993
22. Rosenberg CL, Wong E, Petty EM, Bale AE, Tsujimoto Y, Harris NL, Arnold A: PRAD1, a candidate BCL1 oncogene: Mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci USA 88:9638, 1991
23. Bosch F, Jares P, Camp E, Lopez-Guillermo A, Piris MA, Villamor N, Tassies D, Jaffe ES, Montserrat E, Rozman C, Cardesa A: PRAD-1/Cyclin D1 gene overexpression in chronic lymphoproliferative disorderes: A highly specific marker of mantle cell lymphoma. Blood 84:1716, 1994
24. Oka K, Ohno T, Kita K, Yamaguchi M, Takakura N, Nishii K, Miwa H, Shirakawa S: PRAD1 gene over-expression in mantle-cell lymphoma but not in other low-grade B-cell lymphomas, including extranodal lymphoma. Br J Haematol 86:786, 1994
25. Yang W-I, Zukerberg LR, Motokura T, Arnold A, Harris NL: Cyclin D1 (Bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia. Am J Pathol 145:86, 1994
26. de Boer CJ, van Krieken JHJM, Kluin-Nelemans HC, Kluin PM, Schuuring E: Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma. Oncogene 10:1833, 1995
27. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R: p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413, 1991
28. Cesarnian E, Inghirami G, Chadburn A, Knowles DM: High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol 143:845, 1993
29. El Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R, Newcomb EW: p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82:3452, 1993
30. Bhatia KG, Gutiérrez MI, Huppi K, Siwarski D, Magrath IT: The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. Cancer Res 52:4273, 1992
31. Gutierrez MI, Bhatia K, Diez B, Muriel FS, Epelman S, DeAndreas ML, Huppi K, Magrath I: Prognostic significance of p53 mutations in small non-cleaved cell lymphomas. Int J Oncol 4:567, 1994
32. Cesarman E, Chadburn A, Inghirami G, Gaidano G, Knowles DM: Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations. Blood 80:3205, 1992
33. Sakashita A, Hattori T, Miller CW, Suzushima H, Asou N, Takatsuki K, Koeffler HP: Mutations of the p53 gene in adult T-cell leukemia. Blood 79:477, 1992
34. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, Raffeld M: p53 mutation is associated with progression in follicular lymphomas. Blood 82:1994, 1993
35. LoCoco F, Gaidano G, Louie DC, Offit K, Chaganti RSK, Dalla-Favera R: p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 82:2289, 1993
36. Diccianni MB, Yu J, Hsiao M, Mukherjee S, Shao L-E, Yu AL: Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 84:3105, 1994
37. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148, 1994
38. Beck JS, Kwitek AE, Cogen PH, Metzger AK, Duyk GM, Sheffield VC: A denaturing gradient gel electrophoresis assay for sensitive detection of p53 mutations. Hum Genet 91:25, 1993
39. Sambrook J, Fritsch EF, Maniatis T (eds): Molecular Cloning: A Laboratory Manual (ed 2). Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989
40. Myers RM, Maniatis T, Lerman LS: Detection and localization of single base changes by denaturing gradient gel electrophoresis. Methods Enzymol 155:501, 1987
41. Greiner TC, Raffeld MR, Lutz C, Dick F, Jaffe ES: Analysis of T cell receptor-γ gene rearrangements by denaturing gradient gel electrophoresis of GC-clamped PCR products: Correlation with tumor specific sequences. Am J Pathol 136:46, 1995
42. Cheng J, Haas M: Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 10:5502, 1990
43. Farrell PJ, Allan, GJ, Shanahan F, Vousden KH, Crook T: p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J 10:2879, 1991
44. Duthu A, Debuire B, Romano J, Ehrhart JC, Fiscella M, May E, Appella E, May P: p53 mutations in Raji cells: Characterization and localization relative to other Burkitt's lymphomas. Oncogene 7:2161, 1992
45. Tenaud C, Negoescu A, Labat-Moleur F, Legros Y, Soussi T, Brambilla E: p53 immunolabeling in archival paraffin-embedded tissues: Optimal protocol based on microwave heating for eight antibodies on lung carcinomas. Mod Pathol 7:853, 1994
46. Kaplan GL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
47. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II: Analysis and examples. Br J Cancer 35:1, 1977
48. Carbone D, Chiba I, Mitsudomi T: Polymorphism at codon 213 within the p53 gene. Oncogene 6:1691, 1991
49. Mazars G-R, Jeanteur P, Lynch HT, Lenoir G, Theillet C: Nucleotide sequence polymorphism in a hotspot mutation region of the p53 gene. Oncogene 7:781, 1992
50. Ichikawa A, Hotta T, Takagi N, Tsushita K, Kinoshita T, Nagai H, Murakami Y, Hayashi K, Saito H: Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood 79:2701, 1992
51. Orita M, Suzuki Y, Sekiaya T, Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5:874, 1989
52. Lerman LS, Silverstein K: Computational simulation of DNA melting and its application to denaturing gradient gel electrophoresis. Methods Enzymol 155:482, 1987
53. Sheffield VC, Cox DR, Lerman LS, Myers RM: Attachment of a 40-base-pair G+C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single-base changes. Proc Natl Acad Sci USA 86:232, 1989
54. Abrams ES, Murdaugh SE, Lerman LS: Comprehensive detection of single base changes in human genomic DNA using denaturing gradient gel electrophoresis and a GC clamp. Genomics 7:463, 1990
55. Metzger AK, Sheffield VC, Duyk G, Daneshvar L, Edwards MSB, Cogen PH: Identification of a germ-line mutation in the p53 gene in a patient with an intracranial ependymoma. Proc Natl Acad Sci USA 88:7825, 1991
56. Fukuda I, Ogawa K: Detection of p53 gene mutations in rat hepatocellular carcinoma cell lines by denaturing gradient gel electrophoresis. Mol Carcinog 7:257, 1993
57. Renault B, van den Broek M, Fodde R, Wijnen J, Pellegata NS, Amadori D, Khan PM, Ranzani GN: Base transitions are the most frequent genetic changes at p53 in gastric cancer. Cancer Res 53:2614, 1993
58. Van den Broek MH, Jhanwar SC, Fodde R, Chaganti RSK, Khan P M: p53 mutations in colorectal cancers in the patients of metropolitan New York. Anticancer Res 13:1769, 1993
59. Cazorla M, Hernandez L, Campo E, Peinado MA, Bosch F, Piris MA, Montserrat E, Cardesa A: p53 gene mutations in mantle cell lymphomas. Mod Pathol 8:107A, 1995 (abstr)
60. Finkelstein SD, Williams ME, Swerdlow SH: p53 mutations in centrocytic/mantle cell lymphoma (CC/MCL). Mod Pathol 8:110A, 1995 (abstr)
61. Louie D, Jaslow R, Offit K, Parsa N, Chaganti R: Prognostic significance of p53 overexpression in non-Hodgkin's lymphomas with t(11;14)(q13;q32). Mod Pathol 8:115A, 1995 (abstr)
62. Zoldan MC, Inghirami G, Masuda Y, Vandekerckhove F, Frizzera G: Large cell variants of mantle cell lymphoma (MCL): Cytologic characteristics predict poor outcome. Mod Pathol 8; 124A, 1995 (abstr)
63. Greiner TC, Moynihan MJ, Chan WC, Lytle DM, Weisenburger DD: p53 mutations in mantle cell lymphoma. Mod Pathol 8:111A, 1995 (abstr)
64. Louie DC, Offit K, Jaslow R, Parsa NZ, Muery VVVS, Schluger A, Chaganti RSK: p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Blood 86:2892, 1995
65. Norton AJ, Matthews J, Pappa V, Shamash J, Love S, Rohatiner AZS, Lister TA: Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 6:249, 1995
66. Hartmann A, Rosanelli G, Blaszyk H, Cunningham JM, McGovern RM, Schroeder JJ, Schaid DJ, Kovach JS, Sommer SS: Novel pattern of p53 mutation in breast cancers from Austrian women. J Clin Invest 95:686, 1995
67. Adamson DJA, Dawson AA, Bennett B, King DJ, Haites NE: p53 mutation in the myelodysplastic syndromes. Br J Haematol 89:61, 1995
68. Mori N, Wada M, Yokota J, Terada M, Okada M, Teramura M, Masuda M, Hoshino S, Motoji T, Oshimi K, Mizoguchi H: Mutations of the p53 tumour suppressor gene in haematologic neoplasms. Br J Haematol 81:235, 1992
69. Nakamura H, Said JW, Miller CW, Koeffler HP: Mutation and protein expression of p53 in acquired immunodeficiency syndrome-related lymphomas. Blood 82:920, 1993
70. 1)-positive acute leukemia. Leukemia 10:1547, 1993
71. Feinstein E, Cimino G, Gale RP, Alimena G, Berthier R, Kishi K, Goldman J, Zaccaria A, Berrebi A, Canaani E: p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci USA 88:6293, 1991
72. Nishimura S, Asou N, Suzushima H, Okubo T, Fujimoto T, Osato M, Yamasaki H, Lisha L, Takatsuki K: p53 gene mutation and loss of heterozygosity are associated with increased risk of disease progression in adult T cell leukemia. Leukemia 9:598, 1995
73. Lai J-L, Pruedhomme C, Zandecki M, Flactif M, Vanrumbeke M, Lepelley P, Wattel E, Fenaux P: Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïeses and a high incidence of P53 mutations. Leukemia 9:370, 1995
74. Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J, Haas M: Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol 145:702, 1994
75. Newcomb EW: P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Leuk Lymphoma 17:211, 1995
76. Ichikawa A, Hotta T, Takagi N, Tsushita K, Kinoshita T, Nagai H, Murakami Y, Hayashi K, Saito H: Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood 79:2701, 1992
77. Hunter T, Pines J: Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 79:573, 1994
78. Cordon-Cardo C: Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 147:545, 1995
79. Lukas J, Jadayel D, Bartikova J, Nucleva E, Dyer MJS, Strauss M, Bartek J: BCL-1/cyclin-D1 oncoprotein oscillates and subverts the G1 phase control in B-cell neoplasms carrying the t(11;14) translocation. Oncogene 9:2159, 1994
80. Yano T, Jaffe ES, Longo DL, Raffeld M: MYC rearrangements in histologically progressed follicular lymphomas. Blood 80:758, 1992
81. Ye BH, Lista F, LoCoco F, Knowles DM, Offit K, Chaganti RSK, Dalla-Favera R: Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 262:747, 1993
82. Bastard C, Deweindt C, Kerchaert JP, Lenormand B, Rossi A, Pezzella F, Fruchart C, Duval C, Monconduit M, Tilly H: LAZ3 rearrangements in non-Hodgkin's lymphoma: Correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood 83:2423, 1994
83. Otsuki T, Yano T, Clark HM, Bastard C, Kerckaert JP, Jaffe ES, Raffeld M: Analysis of LAZ3 (BCL-6) status in B-cell non-Hodgkin's lymphomas: Results of rearrangement and gene expression studies and a mutational analysis of coding region sequences. Blood 85:2877, 1995
84. Villuendas R, Piris MA, Algara P, Sánchez-Beato M, Sánchez-Verde L, Martinez JC, Orradre JL, Garcia P, Lopez C, Martinez P: The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood 82:3151, 1993
85. Imamura J, Miyoshi I, Koeffler HP: p53 in hematologic malignancies. Blood 84:2412, 1994